Padcev-Keytruda Coverage Highlights Need for Unified Criteria in Combination Therapy Costs

https://www.dailypharm.com/user/news/343896

[데일리팜][기자의 눈] 키트루다·파드셉 병용 급여가 남긴 숙제

 

 

The health insurance 

 

benefit coverage for 

 

Padcev and Keytruda 

 

combination therapy 

 

has been applied to 

 

first-line treatment of

 

urothelial carcinoma

 

starting this month.

 

---

 

The process,

 

which required

 

separate negotiations by

 

each of the two

 

pharmaceutical companies,

 

highlighted issues

 

regarding fiscal burden

 

coordination for

 

new drug combination

 

therapies.

 

---

 

 

Going forward,

 

consistent criteria

 

must be established

 

for evaluating value

 

and sharing costs

 

in combination therapies.